{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:17:42Z","timestamp":1775056662045,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-026-06444-6","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:40:29Z","timestamp":1775050829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Allogeneic CD56+\u2009cell-based immunotherapy in a patient with Fanconi anemia developing acute myeloid leukemia"],"prefix":"10.1007","volume":"152","author":[{"given":"Mehdi Bakhtiyari","family":"Dovvombaygi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin Shahbaz","family":"Ghasabeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiva","family":"Eskandarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Izadpanah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Mehrab","family":"Safdari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Parkhideh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrshad","family":"Seresht-Ahmadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Hajifathali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-4342","authenticated-orcid":false,"given":"Elham","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,1]]},"reference":[{"issue":"9","key":"6444_CR1","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1016\/j.bbmt.2016.05.021","volume":"22","author":"T Aoki","year":"2016","unstructured":"Aoki T, Koh K, Ikeda Y, Sekinaka Y, Akiyama K, Mori M et al (2016) Addition of high-dose cytarabine to fludarabine-based conditioning for hematopoietic stem cell transplantation for treating Fanconi Anemia patients with advanced myeloid malignancy: a single-center experience and literature review. Biol Blood Marrow Transplant 22(9):1725\u20131728","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"6444_CR2","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-17-3196","volume":"24","author":"AT Bj\u00f6rklund","year":"2018","unstructured":"Bj\u00f6rklund AT, Carlsten M, Sohlberg E, Liu LL, Clancy T, Karimi M et al (2018) Complete remission with reduction of high-risk clones following haploidentical NK-cell therapy against MDS and AML. Clin Cancer Res 24(8):1834\u20131844","journal-title":"Clin Cancer Res"},{"key":"6444_CR3","first-page":"2649","volume":"130","author":"S Cooley","year":"2017","unstructured":"Cooley S, He F, Bachanova V, Vercellotti GM, DeFor TE, Curtsinger J et al (2017) Neurological consequences of cytokine release syndrome following subcutaneous recombinant IL-15 and haploidentical donor natural killer cell therapy for advanced acute myeloid leukemia. Blood 130:2649","journal-title":"Blood"},{"issue":"24","key":"6444_CR4","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1182\/blood-2016-01-583625","volume":"127","author":"RP de Latour","year":"2016","unstructured":"de Latour RP, Soulier J (2016) How I treat MDS and AML in Fanconi anemia. Blood 127(24):2971\u20132979","journal-title":"Blood"},{"issue":"26","key":"6444_CR5","doi-asserted-by":"publisher","first-page":"4279","DOI":"10.1182\/blood-2013-01-479733","volume":"122","author":"RP de Latour","year":"2013","unstructured":"de Latour RP, Porcher R, Dalle JH, Aljurf M, Korthof ET, Svahn J et al (2013) Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European group for blood and marrow transplantation experience. Blood 122(26):4279\u20134286","journal-title":"Blood"},{"key":"6444_CR6","doi-asserted-by":"crossref","unstructured":"Debureaux PE, Sicre de Fontbrune F, Bonfim C, Dalle JH, Buchbinder N, Bertrand Y, Renard C, Forcade E, Fernandes J, Talbot A, Pasquini R (2021) FLAG-sequential regimen followed by bone marrow transplantation for myelodysplastic syndrome or acute leukemia in patients with Fanconi anemia: a Franco-Brazilian study. Bone Marrow Transpl 56(1): 285\u2013288","DOI":"10.1038\/s41409-020-0994-2"},{"issue":"2","key":"6444_CR7","doi-asserted-by":"publisher","first-page":"e12870","DOI":"10.1111\/petr.12870","volume":"21","author":"H Ding","year":"2017","unstructured":"Ding H, Hashem H, Cabral L, Rangarajan H, Abusin G, Lazarus HM, Abu-Arja R (2017) Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia. Pediatric Transpl 21(2):e12870","journal-title":"Pediatric Transpl"},{"issue":"12","key":"6444_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345\u20131377","journal-title":"Blood"},{"issue":"1","key":"6444_CR9","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1182\/hematology.2022000393","volume":"2022","author":"C Dufour","year":"2022","unstructured":"Dufour C, Pierri F (2022) Modern management of Fanconi Anemia. Hematology Am Soc Hematol Educ Program 2022(1):649\u2013657","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"6444_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9583","volume":"12","author":"A Eghbali","year":"2024","unstructured":"Eghbali A, Safdari SM, Yousefi Roozbahani M, Tavajohi K, Hosseini S (2024) Fanconi Anemia: challenges in diagnosis and management\u2014a case series report. Clin Case Rep 12(11):e9583","journal-title":"Clin Case Rep"},{"issue":"7","key":"6444_CR11","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ajh.25810","volume":"95","author":"S Giardino","year":"2020","unstructured":"Giardino S, de Latour RP, Aljurf M, Eikema DJ, Bosman P, Bertrand Y et al (2020) Outcome of patients with Fanconi Anemia developing myelodysplasia and acute leukemia who received allogeneic hematopoietic stem cell transplantation: a retrospective analysis on behalf of EBMT group. Am J Hematol 95(7):809\u2013816","journal-title":"Am J Hematol"},{"issue":"2","key":"6444_CR12","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1615\/CritRevImmunol.2021037644","volume":"41","author":"E Hashemi","year":"2021","unstructured":"Hashemi E, Bjorgaard S, Wang D, Uyemura B, Riese M, Thakar MS et al (2021) NK cell development and function in patients with Fanconi Anemia. Crit Rev Immunol 41(2):35\u201344","journal-title":"Crit Rev Immunol"},{"issue":"4","key":"6444_CR13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.jcyt.2016.12.006","volume":"19","author":"SR Jaiswal","year":"2017","unstructured":"Jaiswal SR, Zaman S, Nedunchezhian M, Chakrabarti A, Bhakuni P, Ahmed M et al (2017) CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: a pilot study. Cytotherapy 19(4):531\u2013542","journal-title":"Cytotherapy"},{"issue":"5","key":"6444_CR14","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00277-013-1953-4","volume":"93","author":"GA Justo","year":"2014","unstructured":"Justo GA, Bitencourt MA, Pasquini R, Castelo-Branco MT, Almeida-Oliveira A, Diamond HR et al (2014) Immune status of Fanconi anemia patients: decrease in T CD8 and CD56dim CD16+ NK lymphocytes. Ann Hematol 93(5):761\u2013767","journal-title":"Ann Hematol"},{"issue":"4","key":"6444_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41375-023-01849-5","volume":"37","author":"KH Lee","year":"2023","unstructured":"Lee KH, Yoon SR, Gong JR, Choi EJ, Kim HS, Park CJ et al (2023) The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients\u2014a randomized trial. Leukemia 37(4):807\u2013819","journal-title":"Leukemia"},{"issue":"1","key":"6444_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56270-6","volume":"16","author":"YR Li","year":"2025","unstructured":"Li YR, Fang Y, Niu S, Zhu Y, Chen Y, Lyu Z et al (2025) Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies. Nat Commun 16(1):1248","journal-title":"Nat Commun"},{"key":"6444_CR17","doi-asserted-by":"crossref","unstructured":"Martinez-Balsalobre E, Guervilly JH, van Asbeck-van der Wijst J, Perez-Oliva AB, Lachaud C (2023) Beyond current treatment of Fanconi Anemia: what do advances in cell and gene-based approaches offer?. Blood Rev 60: 101094","DOI":"10.1016\/j.blre.2023.101094"},{"issue":"12","key":"6444_CR18","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.bbmt.2019.07.014","volume":"25","author":"PA Mehta","year":"2019","unstructured":"Mehta PA, Emoto C, Fukuda T, Seyboth B, Teusink-Cross A, Davies SM et al (2019) Busulfan pharmacokinetics and precision dosing: are patients with Fanconi Anemia different? Biol Blood Marrow Transplant 25(12):2416\u20132421","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"6444_CR19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bjh.12634","volume":"164","author":"R Mitchell","year":"2014","unstructured":"Mitchell R, Wagner JE, Hirsch B, DeFor TE, Zierhut H, MacMillan ML (2014) Haematopoietic cell transplantation for acute leukaemia and advanced myelodysplastic syndrome in Fanconi Anemia. Br J Haematol 164(3):384\u2013395","journal-title":"Br J Haematol"},{"issue":"11","key":"6444_CR20","doi-asserted-by":"publisher","first-page":"e26599","DOI":"10.1002\/pbc.26599","volume":"64","author":"KC Myers","year":"2017","unstructured":"Myers KC, Sauter S, Zhang X, Bleesing JJ, Davies SM, Wells SI, Mehta PA, Kumar A, Marmer D, Marsh R, Brown D (2017) Impaired immune function in children and adults with Fanconi anemia. Pediatric Blood Cancer 64(11):e26599","journal-title":"Pediatric Blood Cancer"},{"key":"6444_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1454427","volume":"15","author":"H Park","year":"2024","unstructured":"Park H, Kim G, Kim N, Ha S, Yim H (2024) Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol 15:1454427","journal-title":"Front Immunol"},{"issue":"15","key":"6444_CR22","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1182\/blood-2010-09-308726","volume":"117","author":"S Quentin","year":"2011","unstructured":"Quentin S, Cuccuini W, Ceccaldi R, Nibourel O, Pondarre C, Pag\u00e8s MP et al (2011) Myelodysplasia and leukemia of Fanconi Anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1\/AML1 lesions. Blood 117(15):e161\u2013e170","journal-title":"Blood"},{"issue":"18","key":"6444_CR23","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1182\/blood-2013-08-453126","volume":"122","author":"D Schneidawind","year":"2013","unstructured":"Schneidawind D, Pierini A, Negrin RS (2013) Regulatory T cells and natural killer T cells for modulation of GVHD following allogeneic hematopoietic cell transplantation. Blood 122(18):3116\u20133121","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-026-06444-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-026-06444-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T13:40:30Z","timestamp":1775050830000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-026-06444-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":23,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6444"],"URL":"https:\/\/doi.org\/10.1007\/s00432-026-06444-6","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,1]]},"assertion":[{"value":"25 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare they have no Conflict of interest or financial relationships to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"79"}}